-
Mashup Score: 0Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal - 10 month(s) ago
French drugmaker Sanofi showcased its vaccine franchise, part of a promise made two years ago to overhaul what the company at the time acknowledged was a lagging part of its business. Ahead of an event in London on Thursday, the company previewed new data from a dozen vaccine products in
Source: Endpoints NewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments - 11 month(s) ago
The U.K. government on Thursday unveiled an $800 million package to bolster the life sciences, highlighting officials’ efforts to grow the industry.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
U.K. unveils $800 million package to bolster life sciences amid concern over #biopharma investments. https://t.co/p1ZdeCVvmL
-
-
Mashup Score: 0FTC files lawsuit to block Amgen's purchase of Horizon Therapeutics - 11 month(s) ago
The FTC sued to block Amgen’s $27.8 billion acquisition of Horizon Therapeutics, signaling possible tougher scrutiny of biopharma takeovers even as the pace of deals starts to mount a comeback.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
The FTC’s intervention into Amgen’s acquisition of Horizon Therapeutics could be a preview of heightened antitrust scrutiny of #biopharma mergers. https://t.co/jp5DkMLsIB
-
-
Mashup Score: 0Baxter to sell biopharma solutions unit for $4.25B to private equity - 12 month(s) ago
The company said it plans to use the proceeds of the sale to pay down its debt.
Source: MedTech DiveCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@baxter_intl to sell #biopharma solutions unit for $4.25B to #privateequity | #divestiture https://t.co/qga201H9GS
-
-
Mashup Score: 0Baxter restructures, kidney care spinoff still planned for 2024 - 1 year(s) ago
CEO José Almeida also said the company is exploring strategic alternatives for its biopharma solutions unit.
Source: MedTech DiveCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@baxter_intl restructures, #kidneycare #spinoff still planned for 2024 - CEO José Almeida also said the company is exploring strategic alternatives for its #biopharma solutions unit. | #medicaldevices https://t.co/FXZjHJqI4f
-
-
Mashup Score: 1
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
Source: ScripCategories: Healthcare Professionals, Latest HeadlinesTweet-
#LifeisGood! A few months ago - well before #EarthDay23 - I spoke with @ScripEleanor at @PharmaScrip on what '23 holds for #biopharma. #Sustainability and #environment impact every industry sector. #Purpose #socialimpact Read more (sub required): https://t.co/17FCBvvH2j https://t.co/NRKkHH4dkH
-
-
Mashup Score: 3Curing disease is the hot new field for AI talent | Semafor - 1 year(s) ago
Advances in artificial intelligence are turning drug discovery into a software problem, enticing Silicon Valley computer scientists to leave Big Tech for biotech.
Source: www.semafor.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @RichShippy: Curing disease is the hot new field for AI talent! #biopharma #healthcare #biotech #AI https://t.co/3rJ3WVshJm
-
-
Mashup Score: 0
BlueRock Therapeutics will utilize Rune Labs’ StriveStudy clinical trial platform and FDA-cleared Apple Watch data-collection tool to monitor Parkinson’s disease.
Source: MobiHealthNewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@Rune_Labs partners with #biopharma company for #Parkinsons #research - @BlueRockTx will utilize Rune Labs' StriveStudy #clinicaltrials platform and #FDA-cleared #AppleWatch data-collection tool to monitor Parkinson's disease | #wearables https://t.co/QwTgW0g5J8
-
-
Mashup Score: 0Measuring the return from pharmaceutical innovation 2021 - 1 year(s) ago
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.
Source: Deloitte United StatesCategories: Future of Medicine, Latest HeadlinesTweet-
The average cost to develop an asset from discovery to launch has increased, while peak sales forecasts have declined compared to 2021. Find out why in our latest #BioPharma innovation report. https://t.co/CnYjox3mDW
-
-
Mashup Score: 0
Welcome! You are invited to join a webinar: Measuring the return from pharmaceutical innovation 2022. After registering, you will receive a confirmation email about joining the webinar.
Source: ZoomCategories: Future of Medicine, Latest HeadlinesTweet-
Register for our upcoming webinar on Feb 28. from 10-11 AM/ET to explore the return from pharmaceutical innovation, and the state of #biopharma R&D since 2010. https://t.co/YPOuAJLHl0
-
Sanofi hints at 'class effect' for #mRNA #flu shot as it unveils #vaccine R&D plans driven by $3.2B deal via @endpts #vaccines #pharma #biotech #biopharma #pharmaceuticals #pharmaceuticalindustry https://t.co/FbDVUaR8Ga https://t.co/ezhFgCEhvZ